A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722).

Trial Profile

A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Robatumumab (Primary) ; Carboplatin; Cetuximab; Cisplatin; Epirubicin; Erlotinib; Everolimus; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Paclitaxel; Trastuzumab
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Feb 2012 Planned end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov
    • 21 Feb 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top